Robert Chess, a director at Twist Bioscience Corp (NASDAQ:TWST), recently sold 5,000 shares of the company's common stock, according to a recent filing with the Securities and Exchange Commission. The shares were sold at a price of $50.00 each, amounting to a total transaction value of $250,000. The transaction price represents a premium to the current trading price of $43.60, with the stock showing notable volatility according to InvestingPro data. Following this sale, Chess holds 16,641 shares directly. Additionally, the Chess 1997 Trust, for which Chess and his spouse are the sole trustees and beneficiaries, owns 42,528 shares indirectly. The transactions were executed under a Rule 10b5-1 trading plan that Chess adopted in August 2024. Twist Bioscience, currently valued at $2.6 billion, maintains strong liquidity with a current ratio of 4.88. InvestingPro analysis reveals 6 additional key insights about TWST's financial health and growth prospects, available in the comprehensive Pro Research Report covering 1,400+ top stocks.
In other recent news, Twist Bioscience Corporation (NASDAQ:TWST) concluded its fiscal year 2024 with robust performance. The company's Q4 revenues rose by 27% to $84.7 million, and the total annual revenue growth was 28%, reaching $330 million. Twist Bioscience also exceeded its gross margin guidance for the quarter, achieving 45.1%, and noted an annual gross margin improvement to 42.6%.
Baird has reaffirmed its Outperform rating on Twist Bioscience and increased the price target to $48.00. TD Cowen also reaffirmed its Buy rating for the company, emphasizing the company's solid financial guidance for fiscal year 2025. Scotiabank (TSX:BNS) raised its price target for the company to $54, maintaining a Sector Outperform rating.
Twist Bioscience's initial guidance for FY25 anticipates revenue growth between 17% to 20% year-over-year, largely driven by the Next (LON:NXT) Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors. The company is also expected to improve its adjusted EBITDA by roughly $30 million year-over-year. These are among the recent developments shaping the future of Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.